Northeast Asia

Asset management firm PGIM Fixed Income has hired Yong Duk Kim as a vice president for client advisory, a newly created position.

HSBC loans banker Ashish Sharma has taken on additional responsibilities, co-leading Asia Pacific leveraged and acquisition finance with Rachel Watson.

New Horizon Health hit the equities market on Thursday, aiming to raise up to HK$2.04bn ($263.1m) from its IPO, according to a source familiar with the matter.

Chinese company Alibaba Group Holding made its long-awaited return to the debt market this week, even as the country’s regulators turned up the heat on the e-commerce giant.

Cloopen Group Holding, a cloud-based communications provider, launched its New York Stock Exchange IPO on Wednesday night.

The Export-Import Bank of Korea got orders of nearly $6bn for a $1.5bn triple-tranche bond this week, showing the continuous appeal of deals from high quality credits.

China Fortune Land Development’s domestic and offshore bonds swung this week after the property company admitted to onshore defaults worth Rmb5.255bn ($813m), adding to ongoing concerns about its liquidity condition and access to funding. Addison Gong reports.

Nomura’s new chief executive is off to a strong start. Mark that down as a point for investment bankers.

A handful of Chinese companies managed to hit the bond market on Wednesday for new deals, ahead of not just the upcoming Chinese New Year break but also the jumbo outing launched by Alibaba Group Holding on Thursday.

Nomura said that net revenues in its investment banking business for the last three months of 2020 were the highest in nine years. Yet while it was a good quarter overall for the firm's wholesale business, revenue fell year on year in Europe, the Middle East and Africa.

China Industrial Securities Co priced its $300m bond at a tighter level than expected due to support from its hefty syndicate team, defying concerns even among some of the banks on the transaction whether the issuer would hit its funding target.

Chinese biopharmaceutical duo WuXi Biologics (Cayman) and InnoCare Pharma raised a combined HK$16.2bn ($2.1bn) on Tuesday from selling new stock.